Cargando…
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Parkinson’s disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer’s disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder,...
Autor principal: | Cacabelos, Ramón |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372567/ https://www.ncbi.nlm.nih.gov/pubmed/28273839 http://dx.doi.org/10.3390/ijms18030551 |
Ejemplares similares
-
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
por: Cacabelos, Ramon
Publicado: (2020) -
Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
por: Cacabelos, Ramón, et al.
Publicado: (2015) -
Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
por: Cacabelos, Ramón, et al.
Publicado: (2021) -
Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders
por: Cacabelos, Ramón
Publicado: (2009) -
Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases
por: Teijido, Oscar, et al.
Publicado: (2018)